Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In commemoration of World Cancer Day on 4 February 2016, CSM statisticians present a TiTE-CRM phase I trial design for testing a chemoradiotherapy intervention in oesophageal cancer.

Computed tomography image of a radiotherapy plan for oesophageal cancer (tumour shown in red), delivered using intensity modulated radiotherapy. The radiotherapy target area is shown in yellow. Image by Maria Hawkins

WorldCancerDay

For more information on this trial:

Similar stories

Patients set to benefit from new guidelines on Artificial Intelligence health solutions

Patients could benefit from a faster and more effective introduction of artificial intelligence (AI) innovations to diagnose and treat disease – thanks to the first international standards for reporting of clinical trials for AI.

Six-month outcomes after treatment for COVID-19 on intensive care units in England

Researchers at the University of Oxford are investigating the long-term health outcomes for patients who have been treated for severe COVID-19 disease in intensive care.

Patients with rheumatic pain increasingly turning to opioids

Reporting at EULAR, researchers found that opioid use by patients with rheumatic and musculoskeletal pain was on the rise in Europe.

Could do better: clinical trial reporting fails to live up to the mark

The statistical analysis and reporting of treatment effects in reports of randomised trials with a binary primary endpoint requires substantial improvement, suggests NDORMS research published in BMC Medicine.

COVID-19 prognosis and prediction models for medical decision-making are flawed, say researchers

The modelling and approach to tackle the hard medical decisions associated with the spread of the COVID-19 virus may be based on weak and overly-optimistic evidence from studies that are biased and unreliable, suggests research published by The BMJ today.

Sponsored place available for the Randomised Controlled Trials Course

The inaugural Doug Altman scholarship will be offered to an LMIC (lower-to-middle-income country) applicant or a student.